Prostatype Genomics AB (PROGEN) — Financial Flexibility Index
Prostatype Genomics AB (PROGEN) has a Financial Flexibility Index of -1.15x as of June 2025. Free cash flow of Skr-8.43 Million (operating CF Skr-8.54 Million minus capex Skr114.50K) represents -1% of total liabilities (Skr7.36 Million). Check Prostatype Genomics AB PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Prostatype Genomics AB Financial Flexibility Index (2016–2024)
Historical Financial Flexibility Index trend for Prostatype Genomics AB across 8 annual periods. See Prostatype Genomics AB (PROGEN) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Prostatype Genomics AB (2016–2024)
Year-by-year free cash flow to debt coverage for Prostatype Genomics AB. For the full company profile including market capitalisation, see Prostatype Genomics AB market cap and net worth.
| Year | Flexibility Index | Free Cash Flow (SEK) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -4.33x | Skr-36.85 Million | Skr-44.71 Million | Skr8.50 Million | ▼ -417.1% |
| 2023 | -0.84x | Skr-20.58 Million | Skr-29.14 Million | Skr24.55 Million | ▲ +85.5% |
| 2022 | -5.77x | Skr-27.69 Million | Skr-27.69 Million | Skr4.80 Million | ▼ -82.6% |
| 2021 | -3.16x | Skr-13.58 Million | Skr-16.08 Million | Skr4.30 Million | ▼ -15.6% |
| 2020 | -2.73x | Skr-14.69 Million | Skr-14.71 Million | Skr5.37 Million | ▼ -287.4% |
| 2018 | -0.71x | Skr-6.37 Million | Skr-9.63 Million | Skr9.03 Million | ▼ -807.7% |
| 2017 | -0.08x | Skr-1.05 Million | Skr-5.71 Million | Skr13.49 Million | ▲ +96.1% |
| 2016 | -2.01x | Skr-9.60 Million | Skr-9.63 Million | Skr4.79 Million | — |